March 23, 2022
Orasis Pharmaceuticals, an emerging ophthalmic pharmaceutical company focused on developing an eye drop to improve near vision for people with presbyopia, announced the completion of its NEAR-1 and NEAR-2 Phase 3 clinical studies.
“Orasis is committed to reshaping vision possibilities by developing a presbyopia eye drop with the patient in mind,” said Elad Kedar, chief executive officer of Orasis. “Completion of this clinical trial milestone is exciting because it puts Orasis in position to be next in market. We look forward to sharing top-line results in the coming months and advancing CSF-1 toward commercialization.”
The multi-center, double-masked, parallel-group clinical trials enrolled more than 600 participants in the U.S. to evaluate the efficacy and safety of CSF-1, Orasis’ eye drop candidate.
Orasis Pharmaceuticals is developing CSF-1, a corrective eye drop for the treatment of presbyopia as an alternative to reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective, safe, comfortable and easy-to-use.
According to Orasis, the company is led by a team of industry executives and eyecare specialists with experience in research, development and commercialization of pharmaceutical drugs, as well as finance and business development.
Other Articles to Explore
Orasis is funded by a group of life science and healthcare investors including the ophthalmology-focused venture capital fund Visionary Ventures, Sequoia Capital, SBI (Japan) Innovation Fund, Bluestem Capital, LifeSci Venture Partners, Maverick Ventures Israel and other private investors. Orasis is based in Herzliya, Israel.
For more information, visit www.orasis-pharma.com.